These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7061100)

  • 1. Tumour cell-antibody interactions. I. In vivo experiments.
    Froese G; Berczi I; Israels LG
    Immunology; 1982 Feb; 45(2):303-12. PubMed ID: 7061100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour cell-antibody interactions. II. In vitro studies.
    Froese G; Berczi I; Israels LG
    Immunology; 1982 Feb; 45(2):313-23. PubMed ID: 6977481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice.
    Wheelock EF; Weinhold KJ; Ingenito GG; Goldstein LT
    J Immunol; 1980 Apr; 124(4):1642-7. PubMed ID: 7365237
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of calcium and glucose uptake by murine leukemia L5178Y cells treated with antiserum.
    Woodcock-Mitchell J; Yang TJ
    J Cell Physiol; 1980 Dec; 105(3):423-9. PubMed ID: 7462334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo.
    Romani L; Puccetti P; Fioretti MC; Mage MG
    Int J Cancer; 1985 Aug; 36(2):225-31. PubMed ID: 3894248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic changes in the murine leukemia L5178Y cells treated with antibodies in the absence of complement activity.
    Yang TJ; Haddad-Khairallah L; Wachtel A
    Exp Mol Pathol; 1981 Aug; 35(1):137-52. PubMed ID: 6166498
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice.
    Trainer DL; Wheelock EF
    Cancer Res; 1984 Jul; 44(7):2897-906. PubMed ID: 6609767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine natural antitumor antibodies. III. Interferon treatment of a natural killer-resistant lymphoma: augmentation of natural antibody reactivity and susceptibility to in vivo natural resistance.
    Miller VE; Pohajdak B; Greenberg AH
    J Natl Cancer Inst; 1983 Aug; 71(2):377-84. PubMed ID: 6576195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of growth of the L5178Y murine lymphoma by means of immunization with radiated L5178Y cells.
    Ramos-Damián M; Gómez-Estrada H; Acosta-Ruiz R; Díaz-Esquivel P; Vázquez-Escobosa C
    Arch Invest Med (Mex); 1982; 13(1):29-31. PubMed ID: 7065806
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor selection in vivo for reduced sensitivity to natural resistance and natural antibodies.
    Chow DA
    J Natl Cancer Inst; 1984 Feb; 72(2):339-46. PubMed ID: 6582320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70.
    Grohmann U; Ullrich SJ; Mage MG; Appella E; Fioretti MC; Puccetti P; Romani L
    Eur J Immunol; 1990 Mar; 20(3):629-36. PubMed ID: 2318253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A search for target cell structures associated with susceptibility to NK cells.
    Henney CS
    Adv Exp Med Biol; 1982; 146():357-66. PubMed ID: 7102463
    [No Abstract]   [Full Text] [Related]  

  • 13. Phenotypic shifts in the L5178Y lymphoma population during progression of the tumor-dormant state in DBA/2 mice.
    Trainer DL; Wheelock EF
    Cancer Res; 1984 Mar; 44(3):1063-71. PubMed ID: 6607108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel tumor-specific antigen(s) response observed in a syngeneic lymphoma-bearing host.
    Manson LA
    Cancer Detect Prev Suppl; 1987; 1():111-20. PubMed ID: 3121177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity as the predominant factor determining metastasis by murine lymphomas.
    Davey GC; Currie GA; Alexander P
    Br J Cancer; 1979 Oct; 40(4):590-6. PubMed ID: 497109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of L5178Y cells from tumor-dormant DBA/2 mice by specific active immunotherapy.
    Marsili MA; Robinson MK; Truitt GA; Wheelock EF
    Cancer Res; 1983 Jan; 43(1):15-21. PubMed ID: 6600159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth in vivo of l5178y-r murine leukaemic cells treated in vitro with cis-dichloro bis-(cyclopentylamine) platinum II.
    Szumiel I; Niepokojczycka E; Godlewska E
    Br J Cancer; 1981 Jan; 43(1):116-7. PubMed ID: 7459232
    [No Abstract]   [Full Text] [Related]  

  • 18. Location of tumoral antigens in L5178Y murine lymphoma cells.
    Ramos-Damián ME; Gómez-Estrada H; Hernández-Delgado J; Tapia-Arizmendi L; Feria-Velasco A
    Arch Invest Med (Mex); 1980; 11(3):425-34. PubMed ID: 7469659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced suppressor macrophage activity associated with termination of the L5178Y cell tumor-dormant state in DBA/2 mice.
    Robinson MK; Truitt GA; Okayasu T; Wheelock EF
    Cancer Res; 1983 Dec; 43(12 Pt 1):5831-6. PubMed ID: 6227383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytotoxic and blocking antibodies in the sera and eluates from spleen cells of mice with Rauscher leukemia following a different course].
    Ter-Grigorov VS; Dzagurov SG; Shevelev BI
    Biull Eksp Biol Med; 1975 Feb; 79(2):76-80. PubMed ID: 48386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.